

Special Issue

Hereditary Syndromes and Radiation

Message from the Guest Editors

About 5% of all cancers are part of a hereditary cancer syndrome. Concerning the use of radiation for cancer treatment, recommendations are established under the assumption that the general population has relatively uniform radiation sensitivity, excluding a few known rare radiation sensitivity-related clinical syndromes. As the availability of genetic tests increases, questions arise in clinical practice as to whether DNA mutations are related to repair pathways that have not been well studied with regard to radiation effects. Potential topics for this Special Issue include, but are not limited to, genetic cancer syndromes, ionizing radiation effects, cell repair mechanisms in genetic cancer syndromes, radiation therapy, ionizing radiation effect diagnostic methods, and new insights into hereditary cancer syndromes.

Guest Editors

Dr. Ana Margarida Abrantes

1. Biophysics Institute of Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (ICBR) Area of Environment Genetics and Oncobiology (CIMAGO), University of Coimbra, 3000-354 Coimbra, Portugal

2. Center for Innovative Biomedicine and Biotechnology (CIBB), 3000-354 Coimbra, Portugal

Prof. Dr. Guillaume Vogin

1. Centre François Baclesse, 4240 Ezch-sur-Alzette, Luxembourg

2. UMR 7365 CNRS-UL IMOPA, Équipe 1, Faculté de Médecine, 54505 Vandœuvre-lès-Nancy, France

Deadline for manuscript submissions

closed (30 September 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/100369

Cancers

Editorial Office

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)